Funding for this research was provided by:
Health Research Foundation of Innovative Medicines Canada
Shriners Hospital for Children
Article History
Received: 4 September 2018
Accepted: 22 January 2019
First Online: 4 February 2019
Compliance with ethical standards
:
: Frank Rauch has received consultancy fees from Alexion Inc. Ghalib Bardai declares no conflict of interest. Cheryl Rockman-Greenberg was principal investigator of Alexion-sponsored clinical trials of enzyme replacement therapy for the treatment of HPP, is a member of the Scientific Advisory Board of the Alexion-sponsored International HPP Registry and has received honoraria for Alexion-sponsored webinar and symposia.